NDC 59368-043 - Tradjenta
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 59368-043
- Package NDCs from labels
- 59368-043-30, 59368-043-90, 59368-043-70, 59368-043-61
- Manufacturer
- Praxis,LLC | Sixarp, LLC
- Effective date
- 2024-07-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Tradjenta - Praxis,LLC | Sixarp, LLC | Praxis,LLC | Sixarp, LLC | 2024-07-08 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Trijardy XR | EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 71873567-9594-452a-bb92-34a129adecac | 2026-08-24 | Boxed warning, Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Jentadueto | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | f6dd9b86-0d18-95d4-2bc7-05591bfdd597 | 2026-08-19 | Boxed warning, Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Jentadueto XR | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 3d02a4d4-d312-80b4-05c4-691b8f0aa7aa | 2026-08-19 | Boxed warning, Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Glyxambi | EMPAGLIFLOZIN AND LINAGLIPTIN | Boehringer Ingelheim Pharmaceuticals, Inc. | ddbab689-f76c-488c-9613-4168d41dd730 | 2026-01-20 | Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Linagliptin and metformin hydrochloride | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | 5cff87ef-97f9-4e3c-9e06-fd257f3cb3fb | 2025-11-04 | Boxed warning, Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Tradjenta | LINAGLIPTIN | Cardinal Health 107, LLC | dfe327e8-f6ab-41e5-bdef-d520118cd83a | 2025-08-27 | Warnings, Adverse reactions | 3X29ZEJ4R2 |
| Tradjenta | LINAGLIPTIN | Boehringer Ingelheim Pharmaceuticals, Inc. | c797ea5c-cab7-494b-9044-27eba0cfe40f | 2025-03-21 | Warnings, Adverse reactions | 3X29ZEJ4R2 |
| 1cc2940c-35bf-99a6-e063-6294a90a0329 | 1cc2940c-35be-99a6-e063-6294a90a0329 | 2024-07-08 | Warnings, Adverse reactions | 1cc2940c-35bf-99a6-e063-6294a90a0329 1cc2940c-35be-99a6-e063-6294a90a0329 | ||
| Tradjenta | LINAGLIPTIN | A-S Medication Solutions | b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1 | 2024-01-22 | Warnings, Adverse reactions | 3X29ZEJ4R2 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.